Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 559

1.

Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections.

Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Claeys G, Lontie M, Van Meensel B, Herman L, Haesebrouck F, Butaye P.

Microb Drug Resist. 2010 Jun;16(2):129-34. doi: 10.1089/mdr.2009.0132.

PMID:
20370505
2.
3.

Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.

Peirano G, Costello M, Pitout JD.

Int J Antimicrob Agents. 2010 Jul;36(1):19-23. doi: 10.1016/j.ijantimicag.2010.02.016. Epub 2010 Mar 31.

PMID:
20359869
4.

Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.

Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.

Antimicrob Agents Chemother. 2007 Jun;51(6):1946-55. Epub 2007 Mar 19.

5.

Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.

Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP.

J Antimicrob Chemother. 2008 Aug;62(2):284-8. doi: 10.1093/jac/dkn181. Epub 2008 May 2.

PMID:
18453527
6.

Fecal carriage of extended-spectrum β-lactamases and AmpC-producing Escherichia coli in a Libyan community.

Ahmed SF, Ali MM, Mohamed ZK, Moussa TA, Klena JD.

Ann Clin Microbiol Antimicrob. 2014 Jun 16;13:22. doi: 10.1186/1476-0711-13-22.

7.

Emergence of extended spectrum-β-lactamase-producing Escherichia coli O25b-ST131: a major community-acquired uropathogen in infants.

Cheng MF, Chen WL, Hung WY, Huang IF, Chiou YH, Chen YS, Lee SS, Hung CH, Wang JL.

Pediatr Infect Dis J. 2015 May;34(5):469-75. doi: 10.1097/INF.0000000000000623.

PMID:
25879646
8.

High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

Peirano G, Richardson D, Nigrin J, McGeer A, Loo V, Toye B, Alfa M, Pienaar C, Kibsey P, Pitout JD.

Antimicrob Agents Chemother. 2010 Mar;54(3):1327-30. doi: 10.1128/AAC.01338-09. Epub 2010 Jan 4.

9.

Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.

Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, Vila J, Garau J.

J Antimicrob Chemother. 2006 Apr;57(4):780-3. Epub 2006 Feb 21.

PMID:
16492721
11.

Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM.

J Antimicrob Chemother. 2004 Oct;54(4):735-43. Epub 2004 Sep 3.

PMID:
15347638
12.

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.

Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, Pérez-Vázquez M, Alcaraz M, García-Cobos S, Campos J.

J Antimicrob Chemother. 2009 Oct;64(4):712-7. doi: 10.1093/jac/dkp288. Epub 2009 Aug 11.

PMID:
19671590
13.

Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals.

Cao X, Cavaco LM, Lv Y, Li Y, Zheng B, Wang P, Hasman H, Liu Y, Aarestrup FM.

J Clin Microbiol. 2011 Jul;49(7):2496-501. doi: 10.1128/JCM.02503-10. Epub 2011 Apr 27.

14.
15.
16.

CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.

Celik AD, Yulugkural Z, Kuloglu F, Eroglu C, Torol S, Vahaboğlu H, Akata F.

J Microbiol Immunol Infect. 2010 Apr;43(2):163-7. doi: 10.1016/S1684-1182(10)60026-6.

17.
18.

Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.

Rodríguez-Baño J, Alcalá J, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.

J Antimicrob Chemother. 2009 Apr;63(4):781-4. doi: 10.1093/jac/dkp028. Epub 2009 Feb 17.

PMID:
19223299
19.

High prevalence of ST131 among CTX-M-producing Escherichia coli from community-acquired infections, in the Czech Republic.

Papagiannitsis CC, Študentová V, Jakubů V, Španělová P, Urbášková P, Žemličková H, Hrabák J.

Microb Drug Resist. 2015 Feb;21(1):74-84. doi: 10.1089/mdr.2014.0070. Epub 2014 Sep 4.

PMID:
25188031
20.

Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients.

Brigante G, Luzzaro F, Perilli M, Lombardi G, Colì A, Rossolini GM, Amicosante G, Toniolo A.

Int J Antimicrob Agents. 2005 Feb;25(2):157-62.

PMID:
15664486

Supplemental Content

Support Center